<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540982</url>
  </required_header>
  <id_info>
    <org_study_id>96032</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-96032</secondary_id>
    <secondary_id>CDR0000567457</secondary_id>
    <nct_id>NCT00540982</nct_id>
  </id_info>
  <brief_title>Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction</brief_title>
  <official_title>Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.

      PURPOSE: This pilot trial is studying the side effects and best dose of vinorelbine in
      treating patients with advanced solid tumors that have not responded to treatment and liver
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To correlate indocyanine green and lidocaine metabolism with vinorelbine ditartrate
           pharmacokinetics in patients with advanced, refractory solid tumors and varying degrees
           of liver dysfunction.

        -  To determine the pharmacokinetics of vinorelbine ditartrate in these patients.

        -  To test a plan of dose adjustment for vinorelbine ditartrate administration in these
           patients.

      OUTLINE: Patients are stratified according to extent of clinical liver dysfunction (normal vs
      mild vs moderate vs severe).

      Patients receive dose-adjusted vinorelbine ditartrate IV over 10 minutes once weekly in the
      absence of disease progression or unacceptable toxicity. Patients achieving an objective
      complete response receive 2 additional courses of study therapy.

      Patients undergo blood sample collection periodically during study for pharmacokinetic and
      pharmacodynamic correlative studies. Blood is also collected after patients receive lidocaine
      IV push and indocyanine green (ICG) IV push. Samples are analyzed for whole blood and plasma
      concentrations of vinorelbine ditartrate and its metabolites by high performance liquid
      chromatography (15) or by liquid chromatography/tandem mass spectrometry assay. Samples are
      also analyzed for ICG clearance and lidocaine hydrochloride metabolic capacity by fluorescent
      polarization immunoassay.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">May 20, 2010</completion_date>
  <primary_completion_date type="Actual">May 20, 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of indocyanine green and lidocaine metabolism with vinorelbine ditartrate pharmacokinetics</measure>
    <time_frame>2 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of vinorelbine ditartrate as measured by high performance liquid chromatography (15) or by liquid chromatography/tandem mass spectrometry assay</measure>
    <time_frame>2 months post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Test of dose adjustment of vinorelbine ditartrate</measure>
    <time_frame>2 months post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>0.5 mg/kg will be administered by IV push to determine clearance</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>1 mg/kg will be administered to determine metabolic capacity</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
    <description>Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>Used to determine plasma concentrations of vinorelbine</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intracellular fluorescence polarization analysis</intervention_name>
    <description>Used to determine concentration of lidocaine metabolic capacity</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid chromatography</intervention_name>
    <description>Used to determine concentrations of vinorelbine and its metabolites</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>Used to determine concentrations of vinorelbine and its metabolites</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Determination of concentrations of vinorelbine and its metabolites</description>
    <arm_group_label>Normal Liver Function</arm_group_label>
    <arm_group_label>Mild Liver Dysfunction</arm_group_label>
    <arm_group_label>Moderate Liver Dysfunction</arm_group_label>
    <arm_group_label>Severe Liver Dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed advanced solid tumor

               -  Any histology allowed

          -  Refractory to standard therapy OR no standard therapy exists

               -  Previously untreated non-small cell lung cancer allowed, provided abnormal liver
                  function is present, defined as moderate (group 3) or severe (group 4)

          -  Measurable disease not required

               -  Present measurable disease requires baseline measurements within 4 weeks of study
                  entry

          -  Patients with acute hepatitis from viral or drug etiologies should recover to a stable
             baseline prior to study therapy

          -  History of brain metastasis allowed, provided the following criteria are met:

               -  Metastasis has been controlled by radiotherapy or surgery

               -  Patient is not currently on corticosteroids

               -  Neurologic status is stable

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Life expectancy ≥ 2 months

          -  ANC = 1,500/mm³

          -  Platelet count = 100,000/mm³

          -  Hemoglobin = 10 g/dL (transfusion to this level allowed)

          -  Creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 60 mL/ min

          -  Patients with EKG evidence of first- or second-degree AV block or left or right bundle
             branch block are ineligible for the lidocaine bolus, but may otherwise be treated on
             this protocol

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No concurrent illness (e.g., cardiovascular, pulmonary, or central nervous system)
             that is poorly controlled or of such severity that the investigator deems unwise to
             enter the patient on protocol

          -  Must have ability to comply with study treatment and required tests

          -  Obstructive jaundice requires a drainage procedure prior to study treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea
             therapy)

          -  No prior radiotherapy to &gt; 30% of the bone marrow or more than standard adjuvant
             pelvic radiotherapy for rectal cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Chao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

